Acurx Pharmaceuticals Files 8-K with Material Agreements
Ticker: ACXP · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1736243
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-update
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K detailing material agreements and equity sales.
AI Summary
On June 17, 2025, Acurx Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and other events. This filing provides updates on the company's corporate activities and financial disclosures.
Why It Matters
This 8-K filing indicates significant corporate actions and potential equity transactions by Acurx Pharmaceuticals, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- June 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Principal executive offices
- 917-533-1469 (phone_number) — Registrant's telephone number
FAQ
What type of Material Definitive Agreement did Acurx Pharmaceuticals enter into?
The filing does not specify the exact nature of the Material Definitive Agreement, only that one was entered into on June 17, 2025.
What was the purpose of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities but does not provide details on the purpose or terms of these sales.
Are there any financial statements included in this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, suggesting that financial information or related documents are included.
When was Acurx Pharmaceuticals, Inc. incorporated?
Acurx Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal business address of Acurx Pharmaceuticals, Inc.?
The principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).